venBio Select Advisor LLC purchased a new stake in Kodiak Sciences Inc. (NYSE:KOD) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 902,200 shares of the company’s stock, valued at approximately $6,406,000. Kodiak Sciences makes up about 0.4% of venBio Select Advisor LLC’s investment portfolio, making the stock its 27th largest holding.
Several other hedge funds and other institutional investors have also made changes to their positions in KOD. Jennison Associates LLC purchased a new stake in shares of Kodiak Sciences in the fourth quarter valued at about $5,662,000. BlackRock Inc. purchased a new stake in shares of Kodiak Sciences in the fourth quarter valued at about $3,139,000. Northern Trust Corp purchased a new stake in shares of Kodiak Sciences in the fourth quarter valued at about $487,000. Geode Capital Management LLC purchased a new stake in shares of Kodiak Sciences in the fourth quarter valued at about $458,000. Finally, Bank of New York Mellon Corp purchased a new stake in shares of Kodiak Sciences in the fourth quarter valued at about $94,000.
Shares of KOD traded down $0.11 on Friday, hitting $6.89. 605 shares of the stock traded hands, compared to its average volume of 62,282. Kodiak Sciences Inc. has a 1 year low of $5.65 and a 1 year high of $11.10.
WARNING: “902,200 Shares in Kodiak Sciences Inc. (KOD) Acquired by venBio Select Advisor LLC” was first posted by Ticker Report and is owned by of Ticker Report. If you are viewing this article on another publication, it was illegally stolen and republished in violation of US and international copyright and trademark laws. The original version of this article can be viewed at https://www.tickerreport.com/banking-finance/4223919/902200-shares-in-kodiak-sciences-inc-kod-acquired-by-venbio-select-advisor-llc.html.
Kodiak Sciences Profile
Kodiak Sciences Inc, a clinical stage biopharmaceutical company, provides novel therapeutics to treat ophthalmic diseases. The company's lead product candidate is KSI-301, a vascular endothelial growth factor (VEGF)-biologic that is in Phase I clinical study to treat wet age-related macular degeneration (AMD) and diabetic retinopathy.
Further Reading: What is Call Option Volume?
Want to see what other hedge funds are holding KOD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kodiak Sciences Inc. (NYSE:KOD).
Receive News & Ratings for Kodiak Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kodiak Sciences and related companies with MarketBeat.com's FREE daily email newsletter.